...
首页> 外文期刊>Revista de la Sociedad Espanola del Dolor >Control de los síntomas en pacientes terminales: efectividad del tratamiento de la disnea irruptiva con opioides
【24h】

Control de los síntomas en pacientes terminales: efectividad del tratamiento de la disnea irruptiva con opioides

机译:控制晚期患者的症状:阿片类药物治疗突破性呼吸困难的疗效

获取原文
           

摘要

Introduction and objective: Breakthrough dyspnea (BD) is frequently suffered by in terminally ill patients. The main objecti- ve of the study was to assess the degree of symptom control for patients admitted to our unit specially the effectiveness of BD therapy in terminally ill patients. Patients and methods: An observational study of a registry of patients was completed and performed at a Spanish hospice care unit. Terminally ill patients presenting with BD and having undergone opioid treatment were selected. BD’s intensity was measured prior to and after treatment using the Borg scale. The intensity of other symptoms was evaluated using the Edmonton Symptom Assessment System (ESAS) scale. Results: One hundred patients were included in the analysis. Males comprised 65 % of the sample, being 55 % oncological patients. Sublingual fentanyl (71 %), intranasal fentanyl (18 %), oral fentanyl (1 %) and subcutaneous morphine (10 %) were administered. Treatment response was observed in 94 % of pa- tients with improvements of two or more points on the Borg Scale for BD, with no differences between treatments. The sa- fety profile was acceptable in all cases. Conclusions: Although opioids are recommended in the first line of treatment of ID, there is not enough scientific evidence to justify its use. It was observed in the study that fentanyl may be an effective and safe therapeutic option for the control of breakthrough dyspnea in terminally ill patients.
机译:简介和目的:绝症患者经常遭受突破性呼吸困难(BD)。该研究的主要目的是评估入院患者的症状控制程度,尤其是对绝症患者进行BD治疗的有效性。患者和方法:在西班牙临终关怀护理部门完成并进行了患者登记的观察性研究。选择患有BD并接受阿片类药物治疗的绝症患者。 BD的强度是在治疗前后使用Borg量表测量的。使用埃德蒙顿症状评估系统(ESAS)量表评估其他症状的强度。结果:100名患者被纳入分析。男性占样本的65%,占55%的肿瘤患者。给予舌下芬太尼(71%),鼻内芬太尼(18%),口服芬太尼(1%)和皮下吗啡(10%)。在94%的患者中观察到治疗反应,BD的Borg量表改善了2个或更多点,治疗之间无差异。在所有情况下,安全配置文件都是可以接受的。结论:尽管在ID治疗的第一线中建议使用阿片类药物,但尚无足够的科学证据证明其使用合理。在研究中观察到,芬太尼可能是控制绝症患者突破性呼吸困难的有效且安全的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号